Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Novobiocin . sodium salt

HSP90 inhibitor
 
BML-A256-0001 1 g 61.00 USD
 
BML-A256-0005 5 g 243.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: ALX-380-093

Antibiotic. Inhibitor of HSP90. Interacts with the C-terminal ATP-binding domain of HSP90 in contrast to the benzoquinone ansamycins 17-AAG (Prod. No. BML-EI308), geldanamycin (Prod. No. BML-EI280), herbimycin A (Prod. No. BML-EI227) and the chemically unrelated radicicol (Prod. No. BML-EI285), which bind to the N-terminal ATP-binding site of HSP90. Inhibitor of DNA gyrase. Useful for the production of positively supercoiled plasma DNA, targeting the nucleotide-binding site of gyrase B. Inhibits retrovirus RNA-dependent DNA polymerase. Potent inhibitor of ADP ribosylation. Inhibits LPS-induced production of pro-inflammatory cytokines, such as TNF-α, IL-1, IL-6 and IL-10. Inhibits protein synthesis and alters the phosphorylation state of several cytosolic proteins. Reverses etoposide resistance in non-P-glycoprotein expressing multidrug resistant (MDR) tumor cell lines. Inducer of CD38 on cells of the myelomonocytic lineage. Forms ion channels in lipid bilayers. Inhibitor of breast cancer resistance protein (BCRP)

Product Specification

Alternative Name:Albamycin, Streptonivicin, N-[7-[[3-O-Aminocarbonyl-6-deoxy-5-C-methyl-4-O-β-L-lyxo-hexapyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-butenyl)benzamide
 
Formula:C31H35N2O11 . Na
 
MW:634.6
 
CAS:1476-53-5
 
MI:14: 6722
 
RTECS:RD5425000
 
Absorbance maximum:307nm
 
Appearance:White to off-white powder.
 
Activity:~900 µg/mg
 
MeltingPoint:220°C
 
Solubility:Soluble in water (100mg/ml), ethanol or DMSO.
 
Shipping:Ambient
 
Long Term Storage:+4°C
 
Handling:Protect from light.
 
380-093
Please mouse over
380-093

Product Literature References

Specific inhibitors of the breast cancer resistance protein (BCRP): A. Pick, et al.; Chem. Med. Chem. 5, 1498 (2010), Abstract;
Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90: J.A. Burlison, et al.; JACS 128, 15529 (2006), Abstract;
Destabilization of the non-pathogenic, cellular prion-protein by a small molecular drug: H.J. Ochel & G. Gademann; Antivir. Ther. 9, 441 (2004), Abstract;
Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions: B.G. Yun, et al.; Biochemistry 43, 8217 (2004), Abstract;
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic: K. Shiozawa,et al.; Int. J. Cancer 108, 146 (2004), Abstract;
A coumermycin/novobiocin-regulated gene expression system: H.F. Zhao, et al.; Hum. Gene Ther. 14, 1619 (2003), Abstract;
Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance: C.H. Gross, et al.; Antimicrob. Agents Chemother. 47, 1037 (2003), Abstract; Full Text
Alteration of Escherichia coli topoisomerase IV to novobiocin resistance: C.D. Hardy & N.R. Cozzarelli; Antimicrob. Agents Chemother. 47, 941 (2003), Abstract; Full Text
Evidence that the novobiocin-sensitive ATP-binding site of the heat shock protein 90 (hsp90) is necessary for its autophosphorylation: T. Langer, et al.; Cell Biol. Int. 26, 653 (2002), Abstract;
Novobiocin is a novel inducer of CD38 on cells of the myelomonocytic lineage: A. Thiele, et al.; Biochim. Biophys. Acta 1542, 32 (2002), Abstract;
Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins: M.G. Marcu, et al.; J. Natl. Cancer Inst. 92, 242 (2000), Abstract;
The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone: M.G. Marcu, et al.; J. Biol. Chem. 275, 37181 (2000), Abstract; Full Text
Immunomodulating properties of the antibiotic novobiocin in human monocytes: A. Luhrmann, et al.; Antimicrob. Agents Chemother. 42, 1911 (1998), Abstract; Full Text
Mechanism of inhibition of vaccinia DNA topoisomerase by novobiocin and coumermycin: J. Sekiguchi, et al.; J. Biol. Chem. 271, 2313 (1996), Abstract; Full Text
The properties of ion channels formed by the coumarin antibiotic, novobiocin, in lipid bilayers: A.M. Feigin, et al.; Biochim. Biophys. Acta 1234, 43 (1995), Abstract;
Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity: J. Zhang et al.; Science 263, 687 (1994), Abstract;
Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity: S. Snyder, et al. ; Science 263, 687 (1994), Abstract;
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin: G. Rappa, et al.; Cancer Res. 53, 58487 (1993), Abstract;
Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A Southwest Oncology Group study.: G.K. Ellis et al.; Cancer 67, 2969 (1991), Abstract;
Novobiocin treatment reverses radiation-induced alterations in higher-order DNA structure in L5178Y nucleoids.: M. Kapiszewska & M. Lange; Radation Res. 127, 285 (1991),
Structure-activity relationships in DNA gyrase inhibitors: S. Radl; Pharmacol. Ther. 48, 1 (1990), (Review), Abstract;
The expression of the DNA ligase gene of Escherichia coli is stimulated by relaxation of chromosomal supercoiling.: J.C. Liebart et al.; Mol. Microbiol. 3, 269 (1989), Abstract;
Inhibition of retrovirus RNA-dependent DNA polymerase by novobiocin and nalidixic acid: Y. Sumiyoshi, et al.; J. Gen. Virol. 64, 2329 (1983), Abstract;
Positively supercoiled plasmid DNA is produced by treatment of Escherichia coli with DNA gyrase inhibitors: D. Lockshon & D.R. Morris; Nucleic Acids Res. 11, 2999 (1983), Abstract;
Eukaryotic DNA repair is blocked at different steps by inhibitors of DNA topoisomerases and of DNA polymerases alpha and beta.: M.R. Mattern et al.; Biochim. Biophys. Acta 697, 6 (1982), Abstract;
Effect of novobiocin and other DNA gyrase inhibitors on virus replication and DNA synthesis in herpes simplex virus type 1-infected BHK cells: B. Francke and J. Margolin; J. Gen. Virol. 52, 401 (1981), Abstract; Full Text
Energy coupling in DNA gyrase and the mechanism of action of novobiocin: A. Sugino, et al.; PNAS 75, 4838 (1978), Abstract; Full Text
Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase: M. Gellert, et al.; PNAS 73, 4474 (1976), Abstract; Full Text
Novobiocin-a specific inhibitor of semiconservative DNA replication in permeabilized Escherichia coli cells: W.L. Staudenbauer; J. Mol. Biol. 96, 201 (1975), Abstract;

Related Products

17-AAG 

HSP90 inhibitor
75747-14-7, Semisynthetic derivative from geldanamycin., ≥98% (TLC) | Print as PDF
 
BML-EI308-0001 1 mg 212.00 USD
Do you need bulk/larger quantities?
 

Geldanamycin 

HSP90 inhibitor
30562-34-6, ≥95% (HPLC) | Print as PDF
 
BML-EI280-0001 1 mg 95.00 USD
 
BML-EI280-0005 5 mg 410.00 USD
Do you need bulk/larger quantities?
 

Herbimycin A 

Tyrosine kinase inhibitor
70563-58-5, ≥98% (HPLC) | Print as PDF
 
BML-EI227-0100 100 µg 158.00 USD
 
BML-EI227-1000 1 mg 904.00 USD
Do you need bulk/larger quantities?
 

Radicicol 

HSP90 inhibitor
12772-57-5, Isolated from Humicola fuscoatra., ≥97% (HPLC) | Print as PDF
 
BML-EI285-0001 1 mg 133.00 USD
Do you need bulk/larger quantities?
 

Related Literature

Product Flyers
Detect Activity of Major ABC Transporter Proteins
Detect Activity of Major ABC Transporter Proteins
Download as PDF

Catalogs
Heat Shock Proteins & the Cellular Stress Response Catalog
Heat Shock Proteins & the Cellular Stress Response Catalog
Download as PDF

Technical Posters
Disease-Associated Stress Signaling
Disease-Associated Stress Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,